Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (4), 556-559
- https://doi.org/10.1016/s0959-8049(01)00408-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupBritish Journal of Cancer, 1998
- The role of gemcitabine in the treatment of other tumours.British Journal of Cancer, 1998
- Gemcitabine: A cytidine analogue active against solid tumorsAmerican Journal of Health-System Pharmacy, 1997
- Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabineInvestigational New Drugs, 1996
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Phase II study of gemcitabine in patients with advanced pancreatic cancerBritish Journal of Cancer, 1996
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of viewCritical Reviews in Oncology/Hematology, 1995
- Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease: An EORTC soft tissue and bone sarcoma group studyEuropean Journal of Cancer and Clinical Oncology, 1990
- Chemotherapy of advanced soft-tissue sarcomas in adultsCancer Treatment Reviews, 1977